0001209191-20-045494.txt : 20200806 0001209191-20-045494.hdr.sgml : 20200806 20200806165456 ACCESSION NUMBER: 0001209191-20-045494 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200605 FILED AS OF DATE: 20200806 DATE AS OF CHANGE: 20200806 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sze Randoll CENTRAL INDEX KEY: 0001751011 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38112 FILM NUMBER: 201082480 MAIL ADDRESS: STREET 1: C/O ATHENEX, INC. STREET 2: 1001 MAIN STREET, SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Athenex, Inc. CENTRAL INDEX KEY: 0001300699 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 431985966 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1001 MAIN STREET STREET 2: SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 BUSINESS PHONE: 716-898-8625 MAIL ADDRESS: STREET 1: 1001 MAIN STREET STREET 2: SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 FORMER COMPANY: FORMER CONFORMED NAME: Kinex Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20131223 FORMER COMPANY: FORMER CONFORMED NAME: Kinex Pharmaceuticals LLC DATE OF NAME CHANGE: 20040817 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-05 0 0001300699 Athenex, Inc. ATNX 0001751011 Sze Randoll C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600 BUFFALO NY 14203 0 1 0 0 Chief Financial Officer Common Stock 5000 D Stock Option (Right to Buy) 17.09 2028-08-20 Common Stock 90000 90000 D Stock Option (Right to Buy) 17.77 2027-10-03 Common Stock 28000 28000 D Stock Option (Right to Buy) 17.30 2028-03-27 Common Stock 10000 10000 D Stock Option (Right to Buy) 13.17 2029-02-28 Common Stock 60000 60000 D Stock Option (Right to Buy) 12.45 2020-06-05 4 A 0 75000 0.00 A 2030-06-05 Common Stock 75000 75000 D This option vests in four equal annual installments beginning on August 20, 2019. This option vests in four equal annual installments beginning on October 3, 2018. This option vests in four equal annual installments beginning on March 27, 2019. This option vests in four equal annual installments beginning on February 28, 2020. These options were granted contingent on receiving shareholder approval of the Amended and Restated 2017 Omnibus Incentive Plan, which approval was received on June 5, 2020. This option vests in four equal annual installments beginning on June 5, 2021. /s/Teresa Bair, Attorney-in-Fact 2020-08-06